GlassScriptPhysician profile
Adam Don Switzer
NPI 1821502931
$3,233.00
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $834 · 2022: $1,208 · 2023: $1,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $475.28 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $391.57 | 2021-2023 | Farxiga, Breztri |
| Lilly USA, LLC | $350.53 | 2021-2023 | Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $243.33 | 2021-2023 | Jardiance |
| Novo Nordisk INC | $223.51 | 2021-2023 | Rybelsus, Ozempic |
| Corium, LLC | $181.21 | 2021-2023 | Azstarys |
| Abbvie INC. | $135.80 | 2021-2023 | |
| Pfizer INC. | $115.56 | 2023 | |
| Merck Sharp & Dohme LLC | $108.70 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $100.22 | 2022-2023 | Rexulti |
| Genentech USA, INC. | $93.45 | 2021-2022 | |
| Idorsia Pharmaceuticals US INC | $88.05 | 2022-2023 | Quviviq |
| Sunovion Pharmaceuticals INC. | $82.20 | 2022 | |
| Nevro Corp. | $77.80 | 2022-2023 | Senza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70.65 | 2022-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.90 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $59.24 | 2022-2023 | |
| Teva Pharmaceuticals USA, INC. | $40.15 | 2023 | Uzedy, Austedo Xr |
| Sumitomo Pharma America, INC. | $38.43 | 2023 | Gemtesa |
| Amarin Pharma, INC. | $37.62 | 2021 | |
| Supernus Pharmaceuticals, INC. | $35.81 | 2021 | |
| Exact Sciences Corporation | $28.64 | 2023 | Cologuard Collection Kit |
| Tactile Systems Technology INC | $25.86 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.08 | 2022 | |
| Amgen INC. | $21.83 | 2021 | |
| Janssen Pharmaceuticals, INC | $20.54 | 2021 | |
| Mylan Specialty L.P. | $18.51 | 2022 | |
| Alkermes, INC. | $17.53 | 2023 | Lybalvi |
| Takeda Pharmaceuticals U.S.A., INC. | $16.19 | 2021 | |
| Eisai INC. | $14.14 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.63 | 2021 | |
| Evoke Pharma, INC. | $12.44 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Switzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.